Skip to Main Content
October 29, 2020

Health Law Daily

US Reaches Deal With Eli Lilly For Experimental SARS-CoV-2 Antibody Treatment

  • October 29, 2020

Reuters (10/28) reports the US “will pay as much as $1.19 billion to Eli Lilly and Co to secure nearly 1 million doses of its experimental [SARS-CoV-2] antibody treatment.” The company “will start delivering 300,000 doses of the treatment, for which it is being paid $375 million, within two months of receiving an emergency use authorization.” According to HHS, the federal government then “has an option to buy an additional 650,000 vials for $812.5 million.”
      The Hill (10/28, Weixel) reports the deal was announced “a day after Lilly said the drug had no clinical benefit for helping hospitalized patients.” However, “the company said it is confident the drug is helpful to those earlier in the course of a [SARS-CoV-2] infection.”